Biodexa Pharmaceuticals (BDRX) Long-Term Deferred Tax (2015 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Long-Term Deferred Tax of $27.3 million for Q4 2025, up 6.76% sequentially from $25.5 million in Q4 2024, and up 6.76% YoY from $25.5 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Long-Term Deferred Tax (2015 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Long-Term Deferred Tax for 11 years, with the latest figure at $27.3 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 6.76% year-over-year to $27.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.3 million (up 6.76% YoY) and the FY2025 annual result came in at $27.0 million, up 5.82% from the prior year.
- Long-Term Deferred Tax rose to $27.3 million in Q4 2025 per BDRX's latest filing, from $25.5 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $27.3 million in Q4 2025 and troughed at $21.0 million in Q4 2022.
- A 5-year average of $24.0 million and a median of $23.5 million in 2023 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax soared 978.3% in 2021, then dropped 7.84% in 2022.
- Over 5 years, Long-Term Deferred Tax stood at $22.8 million in 2021, then dropped by 7.84% to $21.0 million in 2022, then increased by 11.73% to $23.5 million in 2023, then advanced by 8.88% to $25.5 million in 2024, then grew by 6.76% to $27.3 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $27.3 million, $25.5 million, and $23.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27.27 Mn |
| Dec 31, 2024 | 25.54 Mn |
| Dec 31, 2023 | 23.46 Mn |
| Dec 31, 2022 | 21.00 Mn |
| Dec 31, 2021 | 22.78 Mn |
| Dec 31, 2020 | 2.11 Mn |
| Dec 31, 2019 | 2.06 Mn |
| Dec 31, 2018 | 2.19 Mn |
| Dec 31, 2017 | 12.61 Mn |
| Dec 31, 2016 | 10.07 Mn |
| Dec 31, 2015 | 2.47 Mn |